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Kurenai Tanji,7 Eduardo Bonilla,3,7,† Lluı́s Palenzuela,1,2 Israel Fernández-Cadenas,1
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In 2001, we reported linkage of an autosomal dominant form of limb-girdle muscular dystrophy, limb-girdle muscular dystrophy
1F, to chromosome 7q32.1-32.2, but the identity of the mutant gene was elusive. Here, using a whole genome sequencing
strategy, we identified the causative mutation of limb-girdle muscular dystrophy 1F, a heterozygous single nucleotide deletion
(c.2771del) in the termination codon of transportin 3 (TNPO3). This gene is situated within the chromosomal region linked to
the disease and encodes a nuclear membrane protein belonging to the importin beta family. TNPO3 transports serine/arginine-
rich proteins into the nucleus, and has been identified as a key factor in the HIV-import process into the nucleus. The mutation
is predicted to generate a 15-amino acid extension of the C-terminus of the protein, segregates with the clinical phenotype, and
is absent in genomic sequence databases and a set of 4200 control alleles. In skeletal muscle of affected individuals, expres-
sion of the mutant messenger RNA and histological abnormalities of nuclei and TNPO3 indicate altered TNPO3 function. Our
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results demonstrate that the TNPO3 mutation is the cause of limb-girdle muscular dystrophy 1F, expand our knowledge of the
molecular basis of muscular dystrophies and bolster the importance of defects of nuclear envelope proteins as causes of
inherited myopathies.
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Abbreviation: LGMD = limb-girdle muscular dystrophy
Introduction
The limb-girdle muscular dystrophies (LGMDs) comprise a group
of genetically heterogeneous disorders characterized by progres-
sive and predominantly proximal muscle weakness with histolo-
gical signs of degeneration and regeneration in muscle (Bushby,
2009). As a result of molecular characterization and improved
clinical criteria, the classification and nomenclature of LGMDs
have evolved over the last two decades. The canonical categor-
ization of LGMD into autosomal dominant-LGMD (LGMD1) and
autosomal recessive (LGMD2) forms is being refined by a classifi-
cation based on the affected proteins and their correspondent
genes (Nigro et al., 2011)
In 2001, we reported the clinical and morphological phenotype
of a novel form of autosomal dominant-LGMD affecting 32 indi-
viduals in a large Spanish kindred spanning five generations
(Gamez et al., 2001). Clinically, the disorder was characterized
by muscle weakness primarily affecting the pelvic and shoulder
girdles with a wide variability in the age at onset (1–58 years
old), disease progression rate and severity. The disease generally
ran a benign clinical course, but some individuals with childhood
or juvenile onset manifested severe widespread myopathy leading
to wheelchair dependency and respiratory insufficiency. Additional
clinical features of LGMD1F as well as more detailed descriptions
of its time-course and pattern of muscle involvement are pre-
sented here.
Initially, the presence of rimmed vacuoles and filamentous
inclusions in myofibres of affected subjects prompted us to con-
sider a diagnosis of hereditary inclusion body myopathy (Huizing
and Krasnewich, 2009). Hereditary inclusion body myopathy typ-
ically presents as an autosomal recessive trait and is due to mu-
tations in GNE (9p13.3; Genebank NM_005476); however, a few
cases of autosomal dominant hereditary inclusion body myopathy
have also been described and linked to chromosome 17p13.1
(Martinsson et al., 1999) (IBM3 OMIM #605637) or to 7q22.1-
31.1 (Lu et al., 2012) (IBM4). Hereditary inclusion body myopathy
was ruled out in our family because initial genetic analysis using
simple sequence repeat markers indicated that the disorder was
not linked to hereditary inclusion body myopathy. Our subsequent
studies using genome-wide markers demonstrated a novel locus
for this autosomal dominant-LGMD at the chromosomal locus
7q32.1-32.2, between markers D7S1822 and D7S2519, contain-
ing 66 genes. These data confirmed that this family has a genet-
ically distinct form of autosomal dominant-LGMD that was
classified as LGMD1F (Palenzuela et al., 2003) (OMIM
#608423). However, the identity of the mutant gene has been
elusive so far, despite attempts to find it following different
strategies. Here, using a whole genome sequencing approach,
we have identified the causative mutation of the LGMD1F, a
single nucleotide deletion in the termination codon of transportin
3 (TNPO3). The histochemical and ultrastructural findings, to-
gether with the molecular results at DNA, RNA and protein




The reported genealogical investigation of the LGMD1F family (Gamez
et al., 2001) disclosed a common ancestor born in south-eastern Spain
two generations before the oldest living members. The largest branch
originated from Subject II-3 (Gamez et al., 2001) and includes 32
patients with LGMD1F, of whom 28 have been closely followed in
our centre (University Hospital La Fe, València, Spain). Functional ac-
tivity was assessed using the Brooke score (from 1: normal; to 6: no
function for upper extremity) (Brooke et al., 1981) and the Vignos
score (1: able to climb stairs without help; to 10: bedridden for
lower limb function) (Vignos et al., 1963). Muscle strength was
graded using the Modified Medical Research Council (MMRC) scale.
Whole-body muscle imaging was performed on a 1.5 T or 3 T MRI
scanner. Abnormal muscle signal intensity was ranked according to
Mercuri scale (Mercuri et al., 2002): 1, normal appearance; 2, moth-
eaten appearance with scattered small areas of increased signal invol-
ving 530% of muscle volume; 3, moderate involvement (a late moth-
eaten appearance with numerous discrete areas of increased signal
with incipient confluence, involving 30–60% of muscle volume);
4, severe involvement (washed-out or fuzzy appearance due to con-
fluent areas of increased signal, or complete muscle replacement by
connective tissue and fat with only a rim of fascia and neurovascular
structures).
All pedigree identifiers in this report refer to the updated family tree
shown in Supplementary Fig. 1, unless otherwise indicated.
Muscle biopsies
Muscle biopsies from the deltoid or vastus lateralis from 5 of the 32
affected individuals of the family had been performed in the years
1993 and 1994 under informed consent (Gamez et al., 2001) and
stored at 80C at the Neurological Tissue Biobank of Vigo
University Hospital. Frozen muscle specimens from Subjects IV-6, IV-
11 and IV-21 (Supplementary Fig. 1) (Gamez et al., 2001) were
retrieved from the Biobank and further studied by light microscopy.
For ultrastructural studies, original electron microscopy micrographs
were re-examined. Stored Epon-embedded blocks were used to
obtain new ultrathin sections, and were studied under a Philips
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CM100 transmission electron microscope equipped with a digital
camera and the ITEM SYSTEM VELETA (FEI Company) software.
DNA and RNA isolation and
complementary DNA synthesis
DNA was extracted from anticoagulated blood from affected and
unaffected individuals using a standard phenol–chloroform method.
RNA was extracted from skeletal muscle biopsies from Subjects IV-6
and IV-21 and one unrelated healthy control using the RNeasy Kit
(QIAGEN), and treated with the deoxyribonuclease I, amplification
grade (Invitrogen) to eliminate any traces of DNA. Then, complemen-
tary DNA was synthesized using the High Capacity complementary
DNA Reverse Transcription kit, which uses random hexamers
(Applied Biosystems).
Whole genome sequencing
Sequencing libraries were constructed according to the TruSeqTM DNA
sample preparation protocol (Illumina) with minor modifications, in
particular the double size selection. Two micrograms of genomic
DNA were fragmented with a Covaris E210 and size selected to
300–700 bp. Resulting fragments were end-repaired, adenylated,
ligated to Illumina paired-end adaptors and size selected to very
tight sizes using an E-Gel (Life Technologies). Size selected adap-
ter-insert fragments (two insert sizes: 430 bp and 460 bp) were ampli-
fied with 10 PCR cycles and sequenced on an Illumina HiSeq 2000
platform with paired end run of 2  100 bp. Base calling and quality
control was performed on the Illumina RTA sequence analysis pipeline.
Sequence reads were trimmed to the first base with a quality over 30
and mapped to Human genome build hg19 (GRCh37) using GEM
mapper (Marco-Sola et al., 2012), allowing up to four mismatches.
Reads not mapped by GEM mapper (4%) were submitted to a last
round of mapping with BFAST (Homer et al., 2009). Results were
merged and only uniquely mapping non-duplicate read pairs were
used for further analyses. SAM tools suite version 0.1.18 (Li et al.,
2009) with default settings was used to call single nucleotide variants
and short indels. Variants on regions with low mappability (Derrien
et al., 2012), with read depth 510 or with strand bias
P-value5 0.001 were filtered out. The population frequency of the
variants was assessed by comparing to several databases: the 1000
Genomes Project (http://www.1000genomes.org/), NHLBI Exome
Sequencing Project (ESP) release ESP5400 (http://evs.gs.washington.
edu/EVS/), and our internal database of sequence variants identified in
a set of 4100 control samples). The effect prediction was performed
with Annovar version 2011 Dec20 (Wang et al., 2010) and snpEff
version 2.0.5d (Cingolani et al., 2012).
Dideoxy-DNA sequencing
DNA extracted from blood was used to confirm the segregation of the
genotype and the phenotype. A 856 bp fragment encompassing the
last coding sequence of the TNPO3 gene was PCR-amplified (forward,
5’-TCCTCAGTCAAGGACCAACCTACCT-3’; reverse, 5’-TCCTGTAAG
GGCCAAGCATCCCT-3’), and the product was purified (ExoSAP-IT,
Affimetrix) and sequenced using the dideoxy method (BigDye
Terminator v3.1 Cycle Sequencing kit, Applied Biosystems). In
order to analyse the sequences of RNA species, complementary
DNA obtained from skeletal muscle of affected and unaffected indi-
viduals was PCR-amplified (644 bp fragment, exons 20–24,
primers forward 5’-TCTACTACCCTGGACCACCG-3’ and reverse
5’-GCGCTGATTTTCCCTCACAC-3’) and the resulting fragments
were sequenced.
Polymerase chain reaction–restriction
fragment length polymorphism analysis
A 629 bp fragment was PCR-amplified (Forward primer
5’-TCTACTACCCTGGACCACCG-3’ and Reverse primer
5’-CACACCCCCAAACAGGAACT-3’) from skeletal muscle comple-
mentary DNA from Subjects IV-6, IV-21 and one unrelated healthy
control subject. The products were digested with the restriction
enzyme SfaNI (New England Biolabs). The wild-type sequence of the
629 bp amplicon contains a single SfaNI target generating two frag-
ments: 617 bp + 12 bp. The c.2771del mutation generates an add-
itional target, producing the expected restriction fragment pattern of
400 bp + 216 bp + 12 bp. The fragments were resolved by electro-
phoresis in a 2% agarose gel, visualized by ethidium bromide staining,
and the bands were quantitated by densitometry using ImageJ
software.
Western blot
Frozen muscle biopsy samples were homogenized in lysis buffer
containing 0.25% NP-40 with protease inhibitor cocktail (cOmplete
Mini, Roche Diagnostic), and after centrifugation, supernatants
were collected. Concentrations of protein in the supernatants were
measured by bicinchoninic acid assay. Aliquots containing 40mg pro-
tein were separated by SDS-PAGE and transferred to a membrane.
After blocking with PBS containing 0.5% skimmed milk, the mem-
brane was incubated at 4C overnight with primary antibodies: anti-
TNPO3 antibody (ab54353, Abcam 1:50) and anti-beta-actin antibody
(20536-1-AP, Proteintech, 1:1000). The immunoprobed membrane
was washed with PBS containing 0.5% Tween 20 three times, and
was incubated for 1 h at room temperature with peroxidase-conju-
gated anti-mouse IgG antibody or anti-rabbit IgG antibody. After
incubation with secondary antibodies, the membrane was washed
with PBS containing 0.5% Tween 20 three times, and was developed
with ECL Prime Western Blotting Detection Reagents (GE




Six-micrometre thick sections of frozen muscle were fixed in ice-cold
acetone for 10 min, incubated for 1 h with 1% bovine
serum albumin, and stained at 4C for overnight with murine anti-
TNPO3 antibody (ab54353, Abcam) at a concentration of 5 mg/ml.
Specimens were then incubated for 1 h with sheep biotinylated anti-
mouse IgG antibody (RPN1001, GE Healthcare, 1:100) followed by 1 h
with streptavidin-fluorescein (RPN1232, GE Healthcare, 1:250),
mounted, and stained with 4’,6’-diamidino-2-phenylindole dihy-
drochloride (DAPI) using VECTASHIELD Mounting Medium with
DAPI (Vector Laboratories). The stained sections were examined
with a confocal microscope (Leica TCS SP5 II, Leica
microsystems), and images were obtained with LAS AF (Leica
microsystems).
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Results
Clinical assessments
The cohort reported here comprises 30 individuals spanning
Generations III to VI; 13 were included in a previous study
(Gamez et al., 2001). They presented with limb-girdle and distal
muscle weakness with variable distribution, severity, and rate of
progression (Supplementary Table 1). Based on age-at-onset, a
predominant group of juvenile-onset (onset before age 15) was
delineated from an adult-onset form starting in the third and
fourth decades (Gamez et al., 2001). Although a similar distribu-
tion was observed in the present cohort, the difference between
juvenile- and adult-onset groups was not pronounced.
Six patients in the fifth and sixth generations had infantile onset
disease characterized by a mild delay in motor skill (independent
walking was never delayed beyond age 22 months), followed by
difficulty rising from the floor to a standing position and climbing
stairs without the aid of hand rails. Running and jumping were
difficult or impossible. Some manifested an abnormal gait with a
mixture of waddling and distal leg weakness. When walking or
attempting to stand on heels, patients also demonstrated a pecu-
liar posture of the feet with elevation of the big toe, foot drop and
weight-bearing on the lateral soles (Supplementary Fig. 2). In add-
ition, all patients had thin legs and thenar muscle atrophy. Two
patients presented early contractures at the heels, knees, and
elbows with rigid spine and scoliosis reminiscent of Emery-
Dreifuss muscular dystrophy, but lacking cardiac involvement.
Common initial symptoms in the late-childhood and adolescent
group were difficulty running and playing sports. Overt symptoms
of pelvic-femoral weakness, such as difficulty in rising from the
floor or climbing steps, were also frequent. One patient had ex-
ercise intolerance, myalgia and fatigue reminiscent of a metabolic
myopathy.
Symptoms of pelvic-girdle weakness were the most common
presentation in late-onset patients. Weakness and atrophy of
shoulder girdle muscles appeared in only 70% of cases, always
in later or advanced stages of the disease, and usually showing
less degree of involvement than muscles of pelvic-femoral and
axial territories. While both mild (Brook scale 1–2) and severe
(Brook scale 3–4) cases showed minor scapular winging
(Supplementary Fig. 2), prominent scapula alata was never
observed.
Distal muscle involvement was more frequent (at least 24 of 30
patients) than previously reported. In hands, thenar muscle atro-
phy was observed in all 24 carefully assessed patients and a high
proportion of cases reported difficulty grasping a pencil or opening
jars. In lower leg, subclinical muscle weakness was often revealed
by asking patients to stand on their heels. Other symptoms asso-
ciated with the disease were: mild ptosis (five cases), transient
dysphagia (nine cases) and episodic vertigo and ataxia (eight
cases). Three cases had respiratory muscle involvement; all
required non-invasive nocturnal ventilatory support.
The course of the disease was highly variable. The two most
severe cases with an Emery-Dreifuss-like phenotype were wheel-
chair-bound in the third decade. Two other cases reached Vigno
stage 8 at the fifth and seventh decade. Three additional patients
reached Vigno stages 6 and 7 in their forties through sixties. Two
patients died suddenly at age 57 and 78 due to causes unrelated
to the myopathy.
Laboratory investigations provided similar results to those previ-
ously reported (Gamez et al., 2001); however, electromyography
in the current series frequently showed spontaneous activity, and,
in 3 out of 8 patients, displayed clear motor neurogenic features.
In two patients who presented with intense fatigue, ptosis and
transient dysphagia, repetitive stimulation tests and single-fibre
electromyography disclosed no abnormalities in neuromuscular
transmission. Serum creatine kinase levels were also consistent
with the previous report: 40% of the cases showed elevated cre-
atine kinase levels (4500 U/l, maximum 2200). No correlation
between clinical severity and creatine kinase levels was identified.
Muscle MRI demonstrated variable involvement of scapular and
pelvic-femoral muscles, as well as lower leg muscles
(Supplementary Fig. 3). A characteristic relationship between
muscle MRI abnormalities and degree of impairment was observed
with intensity of the MRI signal changes correlating well with the
severity of the clinical involvement. In general, scapular-humeral
girdle muscles were much better preserved than pelvic-femoral
and leg muscles. The percentage of cases with moderate (3) or
severe (4) Mercuri scores by muscle group are: (i) scapular girdle:
teres major (80%), pectoral (64%), infraspinatus and serratus an-
terior (55%), deltoids (46%); (ii) lumbar: paraspinal (90%), ab-
dominal oblique (55%) and rectus abdominus (55%); (iii) thigh:
sartorius (100%), vastus lateralis, intermedius and medialis (73%),
biceps femoris and semitendinosus (55%); and (iv) lower leg:
peroneal (91%), gastrocnemius (91%), soleus (73%) and tibialis
anterior (70%). Correlations between the clinical severity and the
degree of MRI muscle affectation are presented in Supplementary
Fig. 3. Subject V-9 represents a mildly symptomatic subject with-
out overt clinical weakness but with Mercury stage 3 abnormalities
in lumbar paraspinal, sartorius and peronei muscles. Subject V-7
represents a moderately affected subject (Vignos scale 5) showing
a widespread muscle involvement (Mercuri stage 3) of paraverteb-
ral and abdominal lumbar muscles, anterior and posterior thighs
and diffuse lower leg muscles. Finally, Subject IV-26 corresponds
to a severely affected patient (Vignos rating of 7) manifesting
Mercuri 3 and 4 grade abnormalties in scapular, lumbar, thigh
and lower leg muscles.
Histological studies
Previous analyses of muscle biopsies from five people affected
with LGMD1F had revealed increased variability of fibre size and
shape, increased endo- and peri-mysial connective tissue, scattered
degenerating fibres, occasional central nuclei, abnormal intermyo-
fibrillar network with abnormal Z bands, rimmed vacuoles and
abnormally increased mitochondria with rare paracrystalline inclu-
sions (Gamez et al., 2001). These histological features are similar
to those recently reported in the same family (Cenacchi et al.,
2012). New analyses of muscle biopsies from seven affected pa-
tients (Supplementary Fig. 1) confirmed the described abnormal-
ities in myofibres and connective tissue. In addition, we observed
unusually enlarged nuclei with central pallor (Fig. 1). These nuclear
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abnormalities were identified in all seven biopsies in 11.0–25.8%
of muscle fibres (Subject III-14: 18.8%; Subject IV-6: 16.7%;
Subject IV-11: 14.8%; Subject IV-18: 16.0%; Subject IV-21:
17.4%; Subject IV-36: 25.8%; Subject V-14: 11.0%). These per-
centages were derived from counts of the number of affected
nuclei and the total number of fibres within each biopsy in haema-
toxylin–eosin stained slides, using a histometric program (Leica
Application Suite v 3.8.0). We have not observed these nuclear
abnormalities in other myopathies including Duchenne muscular
dystrophy, sarcoglycanopathies, Emery-Dreifuss muscular dystro-
phy due to emerin or lamin A/C mutations, or FHL1 dystrophy.
Ultrastructurally, filamentous inclusions, 18 to 20 nm in diameter,
were detected within nuclei or in the cytosol of a minority of fibres
in two out of five biopsies (Subjects IV-6 and IV-21, Fig. 1). In
three biopsies, corresponding to Subjects IV-6, IV-18 and IV-21,
light microscopy showed rimmed vacuoles and electron
microscopy revealed autophagic vacuoles with prominent pseudo-
myelin structures, membranous whorls and dense bodies.
Immunocytochemical stains for desmin, dystrophin, sarcoglycans,
tau, ubiquitin, and amyloid-b proteins, did not show significant
alteration or accumulation in muscle fibres.
Genetic and molecular studies
Initial strategies to identify the genetic cause of the disease
included sequencing of candidate genes. Among them, FLNC,
encoding filamin c, was extensively investigated because
mutations in this gene cause autosomal dominant myofibrillar my-
opathy (Vorgerd et al., 2005) (OMIM #609524). Studies included
dideoxy-DNA sequencing of FLNC exons, flanking introns and
promoter regions, Southern and northern blot analyses, and
immunohistochemical staining and western blot analyses of
muscle biopsies with anti-FLNC antibodies, and revealed normal
results compared to controls (data not shown) thereby excluding
FLNC as the causative gene.
Dideoxy sequencing of 65 additional genes within the region
failed to reveal potentially pathogenic mutations, although the
presence of heterozygous changes was difficult to be completely
ruled out in some of the electropherograms due to suboptimal
quality. Comparative Genomic Hybridization (CGH, NimbleGen
Systems Inc.) across the linked region excluded genome copy
number variations. Segmentation values across the chromosome
7 regions of interest and other chromosomes showed no differ-
ences in DNA from two control subjects and two affected individ-
uals, thereby excluding DNA copy number alterations as the cause
of the disease (data not shown).
Because studies at the DNA level were unrevealing, we per-
formed analyses of messenger RNA levels. Expression of 36
genes included in the critical region was analysed in RNA extracts
from skeletal muscle of affected members of the family and un-
affected unrelated subjects, using a TaqMan Custom Array 384-
well microfluidic card (Supplementary Fig. 4 and Supplementary
Table 2). No significant differences could be detected in the ex-
pression of the genes analysed, except for a moderate increase of
Figure 1 Light and electron microscopy findings in muscle biopsies. (A and B) Haematoxylin and eosin staining muscle from affected
Subject IV-6. In A, abnormal myonuclei with an ‘empty’ appearance (arrows) (630). Scale bar = 20 mm. In B, note three abnormal nuclei
(arrows) within a myofibre at higher magnification (1000). Scale bar = 10 mm. (C and D) Electron micrographs showing non-branching
tubular filaments 18–20 nm in diameter within a muscle fibre (Subject IV-6). Note myelin and membranous bodies surrounding filaments
(C), which are characteristic of rimmed vacuoles. Original magnifications: 21 000 and 35 000. Scale bars = 0.5 mm.
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NRF1 transcripts and a pronounced increase of LEP transcripts, in
skeletal muscles from affected persons. Because LEP, encoding
leptin, is highly expressed in adipose tissue (Meier and Gressner,
2004), we suspected that elevated LEP expression reflected fat
replacement of affected muscle, rather than a primary pathogenic
alteration. We analysed the expression levels of ADIPOQ, which is
expressed exclusively in adipose tissue (Maeda et al., 1996), and
also found increased levels of this marker of fat tissue in muscles
from affected subjects (Relative quantification (RQ) median; inter-
val: 73.8; 23.9–339.0; n = 5) as compared with levels in un-
affected subjects (RQ median; interval: 3.0; undetectable -10.3;
n = 6). The levels of ADIPOQ transcripts closely correlated with
values for LEP messenger RNA (P40.001; Spearman correlation
coefficient R = 0.991), thus supporting the notion that increases in
LEP transcript reflected fatty replacement of muscle.
After our initial efforts to find the genetic cause of LGMD1F
failed, we applied a more powerful strategy, whole genome
sequencing analysis of DNA from one affected individual
(Subject III-12, Supplementary Fig. 1). After intersecting the results
of whole genome sequencing with the results from previous link-
age analysis (Palenzuela et al., 2003) (chromosome 7: 126 287
120–129 963 917), 3888 variants (3125 single nucleotide variants
and 763 indels) were identified, from which 718 were novel, not
present in the dbSNP database, build 135 (http://www.ncbi.nlm.
nih.gov/projects/SNP/). Additional criteria based on the dominant
inheritance of the disease, the population frequency of the vari-
ants and effect prediction (see ‘Materials and methods’ section),
allowed us to rule out all but one of these variants, a heterozygous
mutation in the termination codon of the TNPO3 gene, encoding
transportin 3, a protein involved in the translocation of proteins
from the cytoplasm to the nucleus (Brass et al., 2008; Cribier
et al., 2011). The mutation (c.2771del, reference sequence
GeneBank NM_012470.3, Fig. 2) is a single adenine nucleotide
deletion in the TAG stop codon, common to the two protein iso-
forms encoded by the gene. The del-A results in conversion of
TAG to TGC codon, encoding cysteine, and extension of the read-
ing frame by 15 codons to a downstream of the termination-signal
within the transcript. Thus, the frameshift leads to the predicted
mutated TNPO3 protein with 15 additional amino acids at the
C-terminus [p.(*924Cysext*15) for isoform 1]. The retrospective
analysis of the sequences of this gene revealed that this hetero-
zygous mutation had been missed in the past due to the poor
quality of the electropherograms. Then, we performed new
dideoxy sequence analysis of TNPO3, which demonstrated pres-
ence of c.2771del in each of the 29 clinically affected individuals
and absence of the mutation in all 20 clinically unaffected relatives
tested. Thus, the sequence data indicate that the mutation segre-
gates with the linked chromosome 7q32.1-32.2 region (Palenzuela
et al., 2003) and with the phenotype (Supplementary Fig. 1).
To investigate whether the mutated messenger RNA was
expressed in skeletal muscle of the affected individuals, comple-
mentary DNA was generated using RNA from two skeletal muscle
samples (Subjects IV-6 and IV-21, Supplementary Fig. 1), and
the 3’-end fragment containing the native stop codon (common
to the 3 transcripts described for the gene, TNPO3 gene entry in
the NCBI, http://www.ncbi.nlm.nih.gov/gene/23534) was PCR-
amplified. Sequence analysis of this amplified complementary
DNA revealed the coexistence of both mutated and wild-type
transcripts in similar amounts, according to the sizes of the
peaks of the two overlapped sequences observed in the electro-
pherograms (Fig. 2). This result was confirmed by PCR-restriction
fragment length polymorphism analysis, which indicated that 61–
64% of the TNPO3 messenger RNA of the two affected individ-
uals contained the mutant form (Fig. 2). Retrospective review of
the real-time PCR results obtained in the microfluidic cards
(Supplementary Fig. 4) confirmed that TNPO3 was expressed in
skeletal muscle of affected and non-affected persons at similar
levels. Taken together, these results demonstrate that the mutated
messenger RNA is stable and does not undergo RNA decay.
We performed western blot analysis of biopsied muscle samples
from four affected subjects and two unaffected control subjects, to
assess changes in amount and molecular weight of TNPO3 protein
(Fig. 2). The TNPO3 mutation in the family disrupts the termin-
ation codon, and is predicted to extend the C-terminus of TNPO3
by 15 amino acids. Using an anti-TNPO3 antibody that recognizes
an N-terminus epitope, present in both normal and mutant
TNPO3, western blot analysis showed a single band at the same
level in muscle from control subjects and affected individuals, and
no extra bands were observed in muscles from affected subjects.
However, the 15 amino acid size difference between normal and
mutant TNPO3 is likely insufficient to distinguish the two proteins
by western blot. Relative to control subject muscles, the amount
of muscle TNPO3 normalized to beta-actin was increased in one
affected subject (Subject IV-36), and decreased in the other three
(Subjects V-14, III-14 and IV-18); therefore, there were no signifi-
cant difference in TNPO3 quantity in mutant versus normal tissue.
To assess the effects of the TNPO3 mutation on TNPO3 cellular
localization, we performed immunohistochemistry of muscle tissue
with anti-TNPO3 antibody. Control muscle stained with anti-
TNPO3 antibody showed clear nuclear staining and that coloca-
lized with DAPI (Fig. 3I). In muscle of affected individuals, TNPO3
immunostaining was also observed within nuclei, but was un-
evenly distributed and often limited to the periphery of nuclei,
(Fig. 3C and F).
Discussion
LGMD1F is one of the nine autosomal dominant forms of LGMD.
Causative genes had been identified for only five forms of auto-
somal dominant-LGMD: MYOT (LGMD1A, OMIM #159000),
LMNA (LGMD1B, OMIM #159001), CAV3 (LGMD1C, OMIM
#607801), DES (LGMD1D, OMIM *125660), and DNAJB6
(LGMD1E, OMIM #603511) (Bushby, 2009; Sarparanta et al.,
2012) (see GeneReviewsTM LGMD Overview). In general, these
disorders are characterized by adult-onset and milder clinical
phenotypes than LGMD2. Although, most individuals harbouring
mutations in these genes fulfil the diagnostic criteria for LGMD,
some manifest a wider spectrum of clinical phenotypes. The ex-
treme example is LMNA mutations, which have been associated
with a broad spectrum of clinical conditions including Dunnigan
lipodystrophy, autosomal dominant Emery-Dreifuss muscular dys-
trophy, cardiomyopathy, Charcot–Marie–Tooth disease and
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Figure 2 Effects of the c.2771del mutation on TNPO3 messenger RNA and protein. (A) The 3’-terminal coding and untranslated region
(UTR) sequences of TNPO3 transcripts, including the 3’-end of the exon 23 (black font) and the 5’-end of the non-coding exon 24
(blue font) of both wild-type and mutant (c.2771del) complementary DNAs. The fragments shown are identical in both transcript variants
1 and 2. The deleted 2771A is labelled with an asterisk. The encoded amino acids are indicated in one-letter code. Changes resulting from
the frame-shifted codons in the mutated sequence are indicated in red case, which highlight the disruption of the native TAG stop codon,
with a modified C-terminus containing 15 extra amino acids p.(*924Cysext*15) relative to normal isoform 1. (B) Electropherograms
showing the complementary DNA sequences from muscle messenger RNA obtained from a healthy control (top, wild-type sequence), and
the affected subject IV-6 (bottom) showing the coexistence of both wild-type and c.2771del mutated transcripts at similar amounts.
Sequences encompass two different exons (exon 23 in black and exon 24 in blue). A similar result was obtained for the Subject IV-21
(data not shown). (C) PCR-restriction fragment length polymorphism analysis of complementary DNA obtained from skeletal muscle
TNPO3 messenger RNA. A 629 bp fragment was PCR-amplified from skeletal muscle complementary DNA from Subjects IV-6, IV-21 and
one unrelated healthy control. The products were digested with the restriction enzyme SfaNI. The wild-type sequence of the 629 bp
amplicon contains one SfaNI site generating two fragments: 617 bp + 12 bp. Because the c.2771del mutation generates an additional
SfaNI site, restriction enzyme digestion produces three fragments: 400 bp + 216 bp + 12 bp. Densitometric analysis of the bands showed
that the mutated messenger RNA was 64% (Subject IV-6) and 61% (Subject IV-21) of total TNPO3 messenger RNA. (D) Western blot of
muscle specimens from affected subjects and controls. Muscle specimens from four subjects with LGMD1F and two control subjects were
analysed by western blot. The anti-TNPO3 antibody showed a clear band at approximately 100 kDa in each lane. No differences in the
position of bands and no extra bands were observed. There were no significant differences in the amounts of TNPO3 normalized to
beta-actin between affected subjects and controls.
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Hutchinson-Gilford progeria (Worman et al., 2009; Bertrand et al.,
2011).
Several lines of evidence strongly support pathogenicity of the
TNPO3 mutation in this family with autosomal dominant-LGMD:
(i) TNPO3 resides within the chromosome 7q32.1-32.2 locus for
LGMD1F; (ii) the mutation segregates with the phenotype; (iii) the
microdeletion is absent in publicly available genomic sequence
databases (dbSNP build 135, 1000 Genomes Project and 5400
NHLBI exomes) and in our set of 4200 Spanish control alleles
indicating that all control individuals harbour the canonical
TNPO3 TAG termination codon in homozygosity at the position
128 597 311 of the chromosome 7; (iv) the mutation in the ter-
mination codon of TNPO3 is predicted to extend the coding
sequence at the 3’-end of the messenger RNA and to generate
an aberrant protein; (v) the mutated messenger RNA is expressed
in the muscle of the affected individuals; and (vi) the detection of
histologically abnormal muscle nuclei with atypical nuclear
filaments, anomalous TNPO3 immunoreactivity and irregular
membranes. These morphological changes of myocyte nuclei
indicate that the TNPO3 c.2771del mutation alters nuclear func-
tions, which is consistent with the putative role of the TNPO3 in
transport of proteins across the nuclear membrane. We observed
similar levels of TNPO3 transcript in skeletal muscle of three
healthy control subjects and in five affected subjects
(Supplementary Fig. 4). It is likely that the mutant protein, which
is predicted to contain 15 additional amino acids at the C-terminus,
is expressed in skeletal muscle and exerts a dominant toxic effect.
Although there is evidence that TNPO3 is expressed in skeletal
muscle (BioGPS portal for annotation resources (http://biogps.org)
(Su et al., 2004), the role of TNPO3 in muscle is currently un-
known. TNPO3 was originally identified as TNP-SR2, which en-
codes a nuclear membrane protein belonging to the importin beta
family and transports serine/arginine (SR) rich proteins into the
nucleus (Lai et al., 2000, 2001). TNPO3 was subsequently identi-
fied by genome-wide RNA interference knockdown as a HIV-de-
pendency factor required for HIV1 infection at a stage between
reverse transcription and integration of HIV in human cells (Brass
et al., 2008; Konig et al., 2008). The protein mediates nuclear
Figure 3 Anti-TNPO3 and DAPI staining of muscle from affected individuals and controls. Immunofluorescence-stained muscle from two
affected individuals (Subject IV-36: A–C, Subject V-14: D–F) and two control subjects (one not shown) (G–I) were observed under a
confocal microscope. Each specimen was stained both with anti-TNPO3 antibody (A, D and G) and by DAPI (B, E and H), and merged
images were generated (C, F and I). TNPO3 staining colocalized with DAPI in control subjects (I). In affected individuals, signals of TNPO3
were also observed within nuclei, but were unevenly distributed (C and F). Scale bar = 40mm.
LGMD1F is caused by a TNPO3 mutation Brain 2013: 136; 1508–1517 | 1515
import of the HIV pre-integration complex by binding the viral
integrase, both in dividing and non-dividing cells (Christ et al.,
2008). The C-terminus domain (CTD) of TNPO3 appears to be
required for interactions with HIV1 integrase (Larue et al., 2012);
therefore, the abnormal extension of the CTD domain is likely to
interfere with its transport function.
Because specific combinations of SR proteins are required for
messenger RNA splicing and post-transcriptional processing
(Bjork et al., 2009), the TNPO3 mutation may alter muscle tran-
scripts raising the possibility that LGMD1F is RNA-mediated
myopathy similar to, but mechanistically distinct from, myotonic
dystrophy (Wheeler and Thornton, 2007; Tang et al., 2012). In
addition, because mutations in the nuclear envelope proteins
emerin and lamin A/C, are known to cause Emery-Dreifuss mus-
cular dystrophy, the TNPO3 mutation causing LGMD1F extends
the genetic spectrum of nuclear envelope-related myopathies. In
support of this notion is the observation of filamentous inclusions
and rimmed vacuoles in all three diseases (Fidzianska et al., 2004).
We have noted filaments of 18 to 20 nm diameter both in nuclei
and within the cytosol of myofibres of affected individuals.
Filaments of similar thickness have been observed in several
muscle disorders and are ascribed to accumulations of proteins,
such as beta-amyloid, tau protein and ubiquitin (Askanas and
Engel, 2006; Askanas et al., 2009). Myonuclear breakdown
would entail the fragmentation of the nuclear membrane and con-
tribute to the formation of pseudomyelin figures and membranous
whorls, which correspond to the rimmed vacuoles seen by light
microscopy.
Interestingly, autophagic vacuoles, which we have observed in
our affected subjects’ muscle, have been also noted in LGMD1D,
which is due to mutations in DNAJB6. In that disease, the pres-
ence of autophagy is due to abnormal protein accumulation,
which confers a dominant toxic function to the autophagic com-
plex that contains the mutated co-chaperone (Sarparanta et al.,
2012). Accordingly, autophagy may be contributing to LGMD1F.
Clinically, LGMD1F was originally described as slowly progres-
sive proximal symmetric weakness with predominantly lower limb
onset, normal to mildly raised creatine kinase activity and myo-
pathic electromyography features (Gamez et al., 2001). Great
variability in age at onset, distribution of muscle involvement
and severity was observed. Two clinical forms were delineated: a
benign adult-onset form presenting in the third decade or later,
and a juvenile form, beginning before age 15 years and leading to
severe functional disability. Relative to the original report, the pre-
sent study of a cohort of 30 patients with LGMD1F provides a
longer and more systematic follow-up, as well as new information
about affected individuals from younger generations. While con-
firming the core phenotype of LGMD1F, which is characterized by
pelvic-femoral weakness and less severe and variable shoulder in-
volvement, the new clinical data also demonstrate a broad clinical
spectrum and novel clinical features of the disease. The disorder
usually begins in childhood or adolescence, and less frequently in
adulthood; and typically runs a benign course compatible with a
normal working life. We noted mild hand and lower leg weakness
producing a stereotyped posture while walking or standing on
heels in virtually all patients. In addition, we observed less common
but well-characterized presentations, including infantile-onset
cases with a congenital myopathy phenotype and a variable
course, which can evolve into a severe and rapid progressive
phenotype. Interestingly, these severely affected patients also
manifested early joint and axial contractures similar to Emery-
Dreifuss syndrome, which raises the possibility of pathogenic
mechanisms distinct from those involved in the typical cases. In
addition, we have also observed very benign patients without
complaints of weakness, but rather atypical features such as
myalgia, exercise intolerance, and fatigue, mimicking a metabolic
myopathy. This broad scenario of clinical nuances highlights the
need to deepen the clinical evaluation of this extensive pedigree
and other potential families with similar gene defects.
In summary, in this report, we have provided an extensive
update of the clinical and morphological features of LGMD1F
and have identified a microdeletion mutation in the TNPO3
gene as a cause of this disorder. This finding expands our know-
ledge on the genetic bases of muscular dystrophies and suggests
that other proteins of the nuclear envelope compartment may play
a primary role in the pathogeneses of muscular dystrophies and
other skeletal muscle-related disorders.
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